| Jeffrey B Trabb, MD | |
|
2670 Crain Hwy, Suite 300, Waldorf, MD 20601-2806 | |
| (301) 632-5750 | |
| (301) 632-5755 |
| Full Name | Jeffrey B Trabb |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 24 Years |
| Location | 2670 Crain Hwy, Waldorf, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790702157 | NPI | - | NPPES |
| D0066391 | Other | MD | MARYLAND |
| 1790702157 | Other | MD | NPI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | D0066391 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Saint Mary's Hospital | Leonardtown, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiology Associates Llc | 5092990952 | 63 |
| Cardiology Associates Llc | 5092990952 | 63 |
News Archive
WellCare Health Plans, Inc. announced today that it has been awarded a Full Health Plan Accreditation for its HealthEase of Florida and WellCare of Florida subsidiaries by URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Plan Accreditation standards include key quality benchmarks for network management, provider credentialing, utilization management, quality management and improvement and consumer protection.
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.
› Verified 2 days ago
| Entity Name | Cardiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396042719 PECOS PAC ID: 5092990952 Enrollment ID: O20110523000017 |
News Archive
WellCare Health Plans, Inc. announced today that it has been awarded a Full Health Plan Accreditation for its HealthEase of Florida and WellCare of Florida subsidiaries by URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Plan Accreditation standards include key quality benchmarks for network management, provider credentialing, utilization management, quality management and improvement and consumer protection.
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.
› Verified 2 days ago
| Entity Name | Medstar Heart Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528345378 PECOS PAC ID: 5698932960 Enrollment ID: O20160226000452 |
News Archive
WellCare Health Plans, Inc. announced today that it has been awarded a Full Health Plan Accreditation for its HealthEase of Florida and WellCare of Florida subsidiaries by URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Plan Accreditation standards include key quality benchmarks for network management, provider credentialing, utilization management, quality management and improvement and consumer protection.
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey B Trabb, MD 106 Irving St Nw, Suite 2700n, Washington, DC 20010-2927 Ph: (202) 877-5800 | Jeffrey B Trabb, MD 2670 Crain Hwy, Suite 300, Waldorf, MD 20601-2806 Ph: (301) 632-5750 |
News Archive
WellCare Health Plans, Inc. announced today that it has been awarded a Full Health Plan Accreditation for its HealthEase of Florida and WellCare of Florida subsidiaries by URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Health Plan Accreditation standards include key quality benchmarks for network management, provider credentialing, utilization management, quality management and improvement and consumer protection.
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Neoprobe Corporation, a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that it recently met with the United States Food and Drug Administration to review the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®.
Results from the study shows that drug, memantine, is no better than a dummy pill when it comes to ameliorating disease symptoms, including the decline of mental abilities and also helping patients with moderate Alzheimer's, the researchers say. Sold under the brand Namenda by Forest Laboratories Inc and Germany's Merz Pharma, the drug had U.S. sales of about $1.2 billion last year.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.
› Verified 2 days ago
Dr. Sailaja Nandipati, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3500 Old Washington Rd, Suite 202, Waldorf, MD 20602 Phone: 301-843-2223 Fax: 301-843-2355 | |
Dr. Zafar Abulhasan Ansari, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7 Post Office Rd Ste E, Waldorf, MD 20602 Phone: 301-396-4800 | |
Firas Al Sammarrai, M.B.CH.B. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10 Saint Patricks Dr, Waldorf, MD 20603 Phone: 301-373-7900 Fax: 301-373-6900 | |
Dr. Alex Ryzhikov, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10 Saint Patricks Dr, Waldorf, MD 20603 Phone: 301-705-7870 Fax: 301-705-7628 | |
Dr. Betty Siu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3510 Old Washington Rd, Suite #100, Waldorf, MD 20602 Phone: 301-609-5200 Fax: 301-609-5220 | |
Dr. Lorenzo Childress Iii, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2855 Crain Hwy, Waldorf, MD 20601 Phone: 240-427-1926 Fax: 240-427-1927 | |
Seetaramayya Nagula, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 12070 Old Line Ctr, Suite 200, Waldorf, MD 20602 Phone: 301-645-8035 Fax: 301-645-5229 |